Purple Biotech
PPBT
6 hedge funds and large institutions have $179K invested in Purple Biotech in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
20% more funds holding
Funds holding: 5 → 6 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
34% less capital invested
Capital invested by funds: $273K → $179K (-$94K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$67K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$35.7K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$26.8K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$13.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$8.93K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$101K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$81K |
| 3 |
MC
Menta Capital
San Francisco,
California
|
-$71K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $67K | +$67K | +15 | New |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $38K | +$35.7K | +8 | New |
|
|
3
Wells Fargo
San Francisco,
California
| $32K | +$13.4K | +3 | +75% |
|
|
OAM
4
Oxford Asset Management
Oxford,
United Kingdom
| $29K | +$26.8K | +6 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $10K | +$8.93K | +2 | New |
|
|
AG
6
Advisor Group
Phoenix,
Arizona
| $3K | – | – | – |
|
|
7
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$101K | -24 | Closed |
|
|
ARTA
8
A.R.T. Advisors
New York
| – | -$81K | -19 | Closed |
|
|
MC
9
Menta Capital
San Francisco,
California
| – | -$71K | -17 | Closed |
|
PPBT Hedge Fund Activity: Q4 2017 in Review
6 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q4 2017, worth a combined $179K — down 34% from $273K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PPBT positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $67K. The largest seller was Deutsche Bank, exiting entirely with an estimated $101K sold.
- 6 institutional investors held Purple Biotech (PPBT) as of Q4 2017, up from 5 in Q3 2017.
- Funds reported $179K of Purple Biotech stock for Q4 2017, down 34% quarter-over-quarter.
- 4 funds opened new Purple Biotech positions in Q4 2017 and 3 closed out, a net change of +1 holder.
- The largest Purple Biotech buyer in Q4 2017 was Virtu Financial, an estimated $67K added.
- The largest Purple Biotech seller in Q4 2017 was Deutsche Bank, an estimated $101K sold.
Based on aggregated 13F filings for Q4 2017.